23 April 2015  
EMA/CHMP/245423/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Invega 
paliperidone 
On 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Invega. The marketing authorisation holder for this medicinal product is Janssen-Cilag International N.V. 
The CHMP adopted an extension to an existing indication as follows2:  
Invega is indicated for the treatment of psychotic or manic symptoms of schizoaffective disorder in 
adults. Effect on depressive symptoms has not been demonstrated. 
For information, the full indications for Invega will be as follows: 
Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. 
Invega is indicated for the treatment of schizoaffective disorder in adults.  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
